Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News (Part 1 of 2)
The world's largest contract research organization, Quintiles Transnational, has been operating in Asia-Pacific region for more than 17 years. Two Quintiles Asia executives, Quintiles India CEO Dr. Ferzaan Engineer and Senior VP and Head of Clinical Development for Quintiles Asia-Pacific Dr. Anand Tharmaratnam, recently shared their views with PharmAsia News on the changing CRO market in the region.
More from Archive
More from Scrip
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.